As of September 30, 2025, Kymera had $978.7 million in cash, cash equivalents and investments. Kymera expects that its cash balance will provide the Company with a cash runway into the second half of 2028, beyond multiple clinical inflection points in our pipeline.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics assumed with a Buy at Guggenheim
- KYMR Upcoming Earnings Report: What to Expect?
- Kymera Therapeutics price target raised to $72 from $54 at BofA
- Kymera Therapeutics’ KT-579 Shows Promising Preclinical Results, Earning Buy Rating from Analyst
- Kymera Therapeutics Advances KT-621 Study for Atopic Dermatitis